Evidence map›Paper›PMID 36962979›Full record

ArticlePLOS global public health2023

Integrating isoniazid preventive therapy into the fast-track HIV treatment model in urban Zambia: A proof-of -concept pilot project.

Mpande Mukumbwa-Mwenechanya, Muhau Mubiana, Paul Somwe, Khozya Zyambo, Maureen Simwenda, Nancy Zongwe, Estella Kalunkumya, Linah Kampilimba Mwango, Miriam Rabkin, Felton Mpesela and 11 more

Full text read
In one paragraph

Article in PLOS global public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mpande Mukumbwa-MwenechanyaCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID https://orcid.org/0000-0002-4753-5075
Muhau MubianaCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.
Paul SomweCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.
Khozya ZyamboMinistry of Health, Lusaka, Zambia.ORCID https://orcid.org/0000-0002-3813-2784
Maureen SimwendaJSI USAID SAFE, Lusaka, Zambia.
Nancy ZongweMinistry of Health, Lusaka, Zambia.
Estella KalunkumyaCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.
Linah Kampilimba MwangoCIHEB, Lusaka, Zambia.
Miriam RabkinICAP at Columbia University and Departments of Medicine & Epidemiology, New York, New York, United States of America.
Felton MpeselaClinton Health Access, Lusaka, Zambia.
Fred ChunguNetwork of Zambian People Living with HIV, Lusaka, Zambia.
Felix MwanzaTreatment Advocacy and Literacy Campaign, Lusaka, Zambia.
Peter PrekoICAP at Columbia University, Mbabane, Eswatini.
Carolyn Bolton-MooreCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.
Samuel BosomprahCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID https://orcid.org/0000-0002-2826-3887
Anjali SharmaCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID https://orcid.org/0000-0002-8189-0732
Khunga MortonMinistry of Health, Lusaka, Zambia.
Prisca KasondeICAP at Columbia University, Lusaka, Zambia.
Lloyd MulengaMinistry of Health, Lusaka, Zambia.
Patrick LinguMinistry of Health, Lusaka, Zambia.
Priscilla Lumano MulengaMinistry of Health, Lusaka, Zambia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most people living with HIV (PLHIV) established on treatment in Zambia receive multi-month prescribing and dispensing (MMSD) antiretroviral therapy (ART) and are enrolled in less-intensive differentiated service delivery (DSD) models such as Fast Track (FT), where clients collect ART every 3-6 months and make clinical visits every 6 months. In 2019, Zambia introduced Isoniazid Preventive Therapy (IPT) with scheduled visits at 2 weeks and 1, 3, and 6 months. Asynchronous IPT and HIV appointment schedules were inconvenient and not client centered. In response, we piloted integrated MMSD/IPT in FT HIV treatment model. We implemented and evaluated a proof-of-concept project at one purposively selected high-volume facility in Lusaka, Zambia between July 2019 and May 2020. We sensitized stakeholders, adapted training materials, standard operating procedures, and screened adults in FT for TB as per national guidelines. Participants received structured TB/IPT education, 6-month supply of isoniazid and ART, aligned 6th month IPT/MMSD clinic appointment, and phone appointments at 2 weeks and months 1-5 following IPT initiation. We used descriptive statistics to characterize IPT completion rates, phone appointment keeping, side effect frequency and Fisher's exact test to determine variation by participant characteristics. Key lessons learned were synthesized from monthly meeting notes. 1,167 clients were screened with 818 (70.1%) enrolled, two thirds (66%) were female and median age 42 years. 738 (90.2%) completed 6-month IPT course and 66 (8.1%) reported IPT-related side effects. 539 clients (65.9%) attended all 7 telephone appointments. There were insignificant differences of outcomes by age or sex. Lessons learnt included promoting project ownership, client empowerment, securing supply chain, adapting existing processes, and cultivating collaborative structured learning. Integrating multi-month dispensing and telephone follow up of IPT into the FT HIV treatment model is a promising approach to scaling-up TB preventive treatment among PLHIV, although limited by barriers to consistent phone access.

Identifiers

PMID36962979
PMCPMC10021523

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read148
identifiers read8
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.